Stereotaxis (NYSEAMERICAN:STXS) Stock Price Down 2.2% – What’s Next?

Shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS) were down 2.2% during trading on Thursday . The stock traded as low as $2.18 and last traded at $2.19. Approximately 271,151 shares traded hands during mid-day trading, a decline of 12% from the average daily volume of 306,758 shares. The stock had previously closed at $2.24.

Stereotaxis Trading Up 6.8 %

The firm has a market capitalization of $198.27 million, a price-to-earnings ratio of -8.36 and a beta of 1.57.

Stereotaxis (NYSEAMERICAN:STXS) last issued its quarterly earnings results on Monday, November 11th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The company had revenue of $9.20 million during the quarter, compared to analyst estimates of $6.80 million. Stereotaxis had a negative net margin of 85.79% and a negative return on equity of 162.54%. On average, equities research analysts predict that Stereotaxis, Inc. will post -0.26 earnings per share for the current fiscal year.

Institutional Trading of Stereotaxis

Institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in Stereotaxis in the third quarter valued at about $39,000. Forum Financial Management LP bought a new stake in Stereotaxis during the 2nd quarter worth approximately $48,000. Jane Street Group LLC raised its holdings in Stereotaxis by 26.9% during the 3rd quarter. Jane Street Group LLC now owns 29,773 shares of the company’s stock worth $61,000 after buying an additional 6,313 shares during the period. Rhumbline Advisers lifted its stake in Stereotaxis by 645.6% in the second quarter. Rhumbline Advisers now owns 48,251 shares of the company’s stock valued at $88,000 after buying an additional 41,780 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of Stereotaxis by 449.9% in the third quarter. Barclays PLC now owns 101,953 shares of the company’s stock valued at $208,000 after buying an additional 83,412 shares during the period. 45.35% of the stock is owned by institutional investors.

Stereotaxis Company Profile

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.